Showing results (61-70 of 146) with videos related to

Sort By:
Pageof 15
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 23, 2025
In Situ Structural Evolution and Activity Descriptor of Atomically Dispersed Catalysts During Nitrate ElectroreductionDaniel S Braga, Angus Pedersen, Mohd Riyaz, et al.
European Journal of Clinical Investigation|August 30, 2024
Biological variability of human intraepithelial lymphocytes throughout the human gastrointestinal tract in health and coeliac diseaseAida Fiz-López, Ángel De Prado, Elisa Arribas-Rodríguez, et al.
Chemical Reviews|November 10, 2022
Bioinspired and Bioderived Aqueous ElectrocatalysisJesús Barrio, Angus Pedersen, Silvia Favero, et al.
Journal of Translational Autoimmunity|February 10, 2025
Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or functionElisa Arribas-Rodríguez, Ángel De Prado, Beatriz de Andrés, et al.
Revista Espanola De Enfermedades Digestivas|December 28, 2016
Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumabCristina Saro, Daniel Ceballos, Fernando Muñoz, et al.
Inflammatory Bowel Diseases|January 8, 2023
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort StudyEsteban Fuentes-Valenzuela, Francisco Javier García-Alonso, Carlos Maroto-Martín, et al.
Revista Espanola De Enfermedades Digestivas|September 4, 2015
Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitisLuis Fernández-Salazar, Jesús Barrio, Fernando Muñoz, et al.
Inflammatory Bowel Diseases|May 12, 2015
Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease PatientsCristina Saro, Daniel Ceballos, Fernando Muñoz, et al.
Pageof 15